Literature DB >> 26976913

Knowing the Prevalence of Familial Hypercholesterolemia Matters.

Anne C Goldberg1, Samuel S Gidding2.   

Abstract

Entities:  

Keywords:  Editorials; cholesterol; congenital; heart defects; hyperlipoproteinemia type II; prevention & control

Mesh：

Year:  2016        PMID： 26976913     DOI： 10.1161/CIRCULATIONAHA.116.021673

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

Review 1.  The panorama of familial hypercholesterolemia in Latin America: a systematic review.

Authors:  Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

2.  Differential impact of severe familial hypercholesterolemia on regional skeletal muscle and organ blood flows during exercise: Effects of PDE5 inhibition.

Authors:  Christian G Aragonez; Vincent J de Beer; Darla L Tharp; Douglas K Bowles; M Harold Laughlin; Daphne Merkus; Dirk J Duncker; Shawn B Bender
Journal:  Microcirculation       Date:  2019-03-26       Impact factor: 2.628

3.  Severe familial hypercholesterolemia impairs the regulation of coronary blood flow and oxygen supply during exercise.

Authors:  Shawn B Bender; Vincent J de Beer; Darla L Tharp; Douglas K Bowles; M Harold Laughlin; Daphne Merkus; Dirk J Duncker
Journal:  Basic Res Cardiol       Date:  2016-09-13       Impact factor: 17.165

4.  Global loss of acetylcholinesterase activity with mitochondrial complexes inhibition and inflammation in brain of hypercholesterolemic mice.

Authors:  Rajib Paul; Anupom Borah
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

5.  Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.

Authors:  Kathleen A Fairman; Lindsay E Davis; David A Sclar
Journal:  Ther Clin Risk Manag       Date:  2017-08-03       Impact factor: 2.423

6.  How Health Care Professionals Evaluate a Digital Intervention to Improve Medication Adherence: Qualitative Exploratory Study.

Authors:  Corline Brouwers; Karen Thomson; Olga C Damman; Martine C de Bruijne; Danielle Rm Timmermans; Marijke Melles
Journal:  JMIR Hum Factors       Date:  2018-02-20

Review 7.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

Authors:  Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

8.  PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients.

Authors:  José Juan Ceballos-Macías; Carolina Lara-Sánchez; Jorge Flores-Real; Carlos Alberto Aguilar-Salinas; Guillermo Ortega-Gutiérrez; Joel Vargas-Sánchez; Ramón Madriz-Prado; Giuseppe Derosa; Hazel Rodríguez-Benítez; Ricardo Baltazar-Romero; Dante José Lopez-Mezquita
Journal:  J Endocr Soc       Date:  2020-11-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.